Phaseline

Targets › TLR9

TLR9 (Toll-like receptor 9): drug programs, companies and trials

14 programs from 13 companies in 22 trials: 9 Phase 1, 9 Phase 2, 3 Phase 3, 1 Phase 4; Oncology, Gastroenterology, Ophthalmology; next expected readout Nov 2026.

Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. (UniProt, Q9NR96)

Open in Phaseline: the race on TLR9, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Taiwan University HospitalHydroxychloroquine
Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist
TLR7, TLR9Phase 4Graves Ophthalmopathy; Steatohepatitis, NonalcoholicJun 2027
University of OxfordHydroxychloroquine
Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist
TLR7, TLR9Phase 3Pneumonia; COVID-19Jan 2027
NYU Langone HealthHydroxychloroquine
Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist
TLR7, TLR9Phase 3Systemic Lupus Erythematosus; Rheumatic DiseaseJan 2028
National Cancer Institute (NCI)CMP-001
TLR9 agonist
TLR9Phase 2Clinical Stage III Cutaneous Melanoma AJCC v8Dec 2026
Abramson Cancer Center at Penn MedicineHydroxychloroquine
Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist
TLR7, TLR9Phase 2Breast Cancer Stage IIB; Breast CancerJan 2027
Medical University of South CarolinaHydroxychloroquine
Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist
TLR7, TLR9Phase 2Ovarian Cancer; Prostate Cancer RecurrentMay 2027
Idera PharmaceuticalsTilsotolimod
Toll-like receptor 9 agonist
TLR9Phase 2Solid Tumor; Malignant Melanoma–
NYU Langone HealthCpG1018
TLR9 agonist
TLR9Phase 1Mild Cognitive ImpairmentNov 2026
National Cancer Centre, SingaporeACM-CpG
CpG-B TLR9 agonist
TLR9Phase 1Advanced Solid TumorDec 2026
West Virginia UniversityHydroxychloroquine sulfate
Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist
TLR7, TLR9Phase 1Adenocarcinoma of the PancreasJun 2027
TriSalus Life SciencesSD-101
TLR9 agonist
TLR9Phase 1Locally Advanced Pancreatic Adenocarcinoma; Hepatocellular CarcinomaSep 2027
Brown UniversityACM-CpG
TLR9 agonist
TLR9Phase 1Malignant AscitesJul 2028
Second Affiliated Hospital of Guangzhou Medical UniversityCpG-ODN
Toll-like receptor 9 (TLR9) agonist
TLR9Phase 1Lung CancerJun 2029
Xingchen PengHydroxychloroquine Sulfate
Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist
TLR7, TLR9Phase 1Radiation-induced Oral Mucositis–

Conditions

Breast Cancer (2) Adenocarcinoma of the Pancreas (1) Breast Cancer Stage IIB (1) Graves Ophthalmopathy (1) Steatohepatitis, Nonalcoholic (1) Mild Cognitive Impairment (1) Advanced Solid Tumor (1) Solid Tumor (1) Malignant Melanoma (1) Ovarian Cancer (1) Prostate Cancer Recurrent (1) Clinical Stage III Cutaneous Melanoma AJCC v8 (1)

Modalities

small molecule (7), mixed (6)

Companies

NYU Langone Health (2) West Virginia University (1) Abramson Cancer Center at Penn Medicine (1) National Taiwan University Hospital (1) National Cancer Centre, Singapore (1) Idera Pharmaceuticals (1) Medical University of South Carolina (1) National Cancer Institute (NCI) (1) Brown University (1) Xingchen Peng (1) University of Oxford (1) TriSalus Life Sciences (1) Second Affiliated Hospital of Guangzhou Medical University (1)

Related targets

TLR7 (7)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.